Kilogram-scale highly selective catalytic
hydrogenation of the
aryl nitro group in the intermediate of crizotinib has been developed,
which adopted continuous-flow technology with prepassivated Raney
Ni as a catalyst at room temperature. According to the reaction condition
optimization, side reactions such as dehalogenation, debenzylation,
and reduction of other unsaturated functional groups were inhibited
eminently. Moreover, catalytic hydrogenation of (R)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)-2-nitropyridine (compound I) afforded the desired product (R)-3-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]pyridin-2-amine
(compound II) with high selectivity (99.9%) and high
conversion (99.5%). Finally, high-quality crizotinib was synthesized
from intermediate II.